Diabetes management increasingly depends on devices that make self-administration simpler, safer, and more precise. As chronic disease incidence continues to rise, patients and healthcare providers alike are looking for solutions that reduce clinical workload, minimize needle-stick injuries, and prevent medication waste. Among the technologies addressing these needs, the two-step automatic pen injector for diabetes stands out as a practical answer to the everyday challenges of insulin and other injectable therapies.
The Prefilled Automatic Pen Injector Assembly (Two-Step) is positioned as a disposable, spring-driven auto-injection device designed specifically to address needle anxiety and the manual force limitations many patients experience during self-injection. For individuals managing diabetes, these two factors are often the biggest barriers to consistent, confident self-administration.
The device's differentiated value comes from two core features working together. First, a hidden needle design keeps the injection process discreet and less intimidating, directly targeting the psychological barrier of needle anxiety. Second, an automatic locking shield engages immediately after injection, reinforcing compliance and reducing the risk of accidental needle exposure after use. Together, these features reflect a design philosophy centered on patient comfort without compromising dosing accuracy.
This two-step mechanism simplifies what has traditionally been a multi-step, manually intensive process. By automating both the needle insertion and the medication delivery sequence, the injector reduces the physical effort required from the patient, which is particularly valuable for individuals with limited hand strength or dexterity—common concerns among long-term diabetes patients.
The Prefilled Automatic Pen Injector Assembly (Two-Step) is developed by Wuxi NEST Biotechnology Co., Ltd., operating under the NEST brand. Founded in 2018, the company strategically positioned itself within the pharmaceutical packaging materials sector, focusing on injection and inhalation delivery methods. NEST describes its mission as empowering the global advancement of drug-device combinations through smarter, more targeted treatment and precision dosing.
What distinguishes NEST's approach is its full in-house industry chain, spanning independent mold design and research and development, automated mass production, and global logistics. This vertically integrated model allows the company to maintain consistency from initial concept to finished product delivery. NEST also conducts Freedom to Operate (FTO) analysis across major global markets, including China, the United States, the United Kingdom, and Europe, helping to mitigate patent-related risks for its pharmaceutical partners during product development and commercialization.
Behind every pen injector is a manufacturing infrastructure built for precision. NEST operates 10,600 square meters of Class 100,000 cleanrooms, 3,600 square meters of Class 10,000 cleanrooms, and a dedicated 2,300 square meter pen injector workshop. Quality oversight is supported by a 76-person specialized quality team and a 50-person mold maintenance team, ensuring that the independent mold center—responsible for delivering over 300 precision molds—maintains consistent output standards.
On the technical side, NEST applies 100% multi-angle CCD camera inspection during production and utilizes moist heat sterilization capabilities achieving a Sterility Assurance Level (SAL) of 10⁻⁶. The company's proprietary cross-linked siliconization technology further supports stable gliding performance in syringes and cartridges, a detail that matters for consistent, comfortable injections.
Regulatory credibility is central to NEST's positioning in the drug-device combination space. The company holds a range of certifications, including ISO 9001, ISO 13485, ISO 11137, ISO 15378, and IATF 16949, along with CE MDR Certification and MDSAP Five-Country Certification covering the United States, Canada, Australia, Japan, and Brazil. In the United States specifically, NEST has secured FDA 510(k) clearances (K240961, K240774) and US DMF filings (No. 40744, No. 42439, No. 40922). Canada Medical Device Licenses (No. 113733, No. 112619) and a China Class II Medical Device Certificate round out its regulatory footprint. Notably, NEST has been identified as a provider of the first moist heat sterilized cartridges in China, reflecting its early engagement with advanced sterilization methods in the domestic market.
While the two-step automatic pen injector addresses a specific set of patient needs, NEST's broader Injection Pen Line offers options suited to different clinical scenarios within chronic disease management, including diabetes and growth hormone deficiency. This includes the Disposable Pen Injector, a three-step liquid medicine injection device offering customizable dosage options ranging from 36 to 80 units, with an injection start force of no more than 10 N for doses up to 60 IU. The TSA Disposable Pen Injector features an internal-rotation design with no outward-extending components during dose adjustment, while the Self-locking Pen Injector (100 IU) and Disposable Fixed-dose Pen Injector provide additional dosing configurations. For patients requiring longer-term use, the Reusable Pen Injector supports over 3,000 cycles and accommodates both IU and mg scaling, offering flexibility for varied treatment regimens. A Prefilled Automatic Pen Injector Assembly (Three-Step) variant is also available for scenarios requiring an alternative delivery sequence.
NEST's operations extend well beyond its Wuxi headquarters. The company maintains subsidiaries and warehouses in Woodbridge, New Jersey and Phoenix, Arizona in the United States; Hendrik-Ido-Ambacht in the Netherlands; Sharjah in the United Arab Emirates; Yokohama, Japan; and Istanbul, Turkey. This integrated warehousing network across the US, Europe, and Asia is designed to shorten lead times for pharmaceutical partners worldwide.
NEST's service model follows a one-stop approach, encompassing research and development, production, pre-sterilization, and customized assembly. Services also include pre-sales customization, technical validation, and automated assembly line planning. The company works alongside global pharmaceutical companies on final device assembly and drug-device combination validation, supporting insulin, GLP-1, and FSH manufacturers, along with research institutions and hospitals across the biopharmaceutical, medical aesthetics, and life sciences industries.
For pharmaceutical companies and healthcare stakeholders evaluating self-administration solutions, the two-step automatic pen injector for diabetes represents a thoughtfully engineered response to two persistent challenges: needle anxiety and physical strain during injection. Backed by Wuxi NEST Biotechnology Co., Ltd.'s vertically integrated manufacturing, extensive international certifications, and global service infrastructure, this device reflects the company's broader commitment to smarter, more targeted treatment and precision dosing—supporting both patients and the pharmaceutical partners who serve them.
